EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been introduced into the first-line treatment of non-small cell lung cancer (NSCLC) after the discovery of kinase-activating mutations of the EGFR gene (Nan et al., 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.